In one paragraphArticle in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Krzysztof DrygalskiDepartment of Hypertension and Diabetology, Medical University of Gdansk, 80-214 Gdansk, Poland.ORCID 0000-0003-0645-7020 Mateusz MaciejczykDepartment of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0001-5609-3187 Urszula MikszaClinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-2612-8796 Andrzej UstymowiczDepartment of Radiology, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0001-7007-6666 Angelika BuczyńskaClinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0001-7403-6928 Andrzej ChomentowskiDepartment of Biophysics, Medical University of Bialystok, 15-089 Bialystok, Poland.
Iga WalczakDepartment of Biochemistry, Medical University of Gdansk, 80-214 Gdansk, Poland.
Karolina PietrowskaClinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-6639-2823 Cezary PawlukianiecStudents Scientific Club "Biochemistry of Civilization Diseases", Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-2675-229X Przemysław CzajkowskiClinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0001-8968-4063 Joanna FiedorczukClinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.
Monika MorozClinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.
Beata ModzelewskaDepartment of Biophysics, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-1051-7906 Anna ZalewskaExperimental Dentistry Laboratory, Medical University of Bialystok, 15-089 Bialystok, Poland.
Barbara Kutryb-ZającDepartment of Biochemistry, Medical University of Gdansk, 80-214 Gdansk, Poland.ORCID 0000-0002-3324-9246 Tomasz KleszczewskiDepartment of Biophysics, Medical University of Bialystok, 15-089 Bialystok, Poland.
Michał CiborowskiClinical Research Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0003-3729-0518 Hady Razak HadyClinical Department of General and Endocrine Surgery, Medical University of Bialystok, 15-089 Bialystok, Poland.
Edyta Adamska-PatrunoClinical Research Support Centre, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-8805-0744 Funding
Foundation for Polish Science Krzysztof Drygalski was supported by the Foundation for Polish ScienceNational Science Center 2018/31/N/NZ7/03242National Science Center 2020/04/X/NZ7/01134
6 · The paper itselfAbstract
Phloroglucinol (PHG), an analgesic and spasmolytic drug, shows promise in preventing high-fat-diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) and insulin resistance. In Wistar rats, 10 weeks of PHG treatment did not prevent HFD-induced weight gain but significantly mitigated fasting hyperglycemia, impaired insulin responses, and liver steatosis. This protective effect was not linked to hepatic lipogenesis or AMP-activated protein kinase (AMPK) activation. Instead, PHG improved mitochondrial function by reducing oxidative stress, enhancing ATP production, and increasing anti-oxidant enzyme activity. PHG also relaxed gastric smooth muscles via potassium channel activation and nitric oxide (NO) signaling, potentially delaying gastric emptying. A pilot intervention in pre-diabetic men confirmed PHG's efficacy in improving postprandial glycemic control and altering lipid metabolism. These findings suggest PHG as a potential therapeutic for NAFLD and insulin resistance, acting through mechanisms involving mitochondrial protection, anti-oxidant activity, and gastric motility modulation. Further clinical evaluation is warranted to explore PHG's full therapeutic potential.
Indexed as
Hypoglycemic AgentsInsulin ResistanceNon-alcoholic Fatty Liver DiseasePhloroglucinolAnimalsAntioxidantsDiet, High-FatDisease Models, AnimalHumansMaleMitochondriaOxidative StressRatsRats, WistarAntioxidantsHypoglycemic AgentsPhloroglucinolanti-spasmodicdiabetesinsulin resistancelipid metabolismliver steatosisNAFLDoxidative stressphloroglucinol
Identifiers
PMID39408621
PMCPMC11477119
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390